Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

Summary

This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.

Timeline

Start

2024-08-29

Primary completion

2026-08-12

Completion

2027-02-12

Drugs

Indications